Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy

Phase 2

Completed

Conditions: Locally Recurrent/Metastatic Triple Negative Breast Cancer

Interventions: Radiation: external beam radiation therapy
Drug: cisplatin
Procedure: Biopsy of Target Tumor

First Posted Date: 2015-04-21

Last Posted Date: 2024-02-09

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 49

Registration Number: NCT02422498

Locations: 🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States

and more 4 locations

Characterization of Hyperpolarized Pyruvate MRI Reproducibility

Not Applicable

Recruiting

Conditions: Malignant Solid Tumors

Interventions: Drug: Hyperpolarized Pyruvate

First Posted Date: 2015-04-20

Last Posted Date: 2025-05-23

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 109

Registration Number: NCT02421380

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Bergen (Consent only ), Montvale, New Jersey, United States

Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin

Phase 1

Active, not recruiting

Conditions: Malignant Pleural Disease
Lung Cancer
Metastases
Mesothelioma
Breast Cancer

Interventions: Genetic: iCasp9M28z T cell infusions
Drug: pembrolizumab
Drug: cyclophosphamide

First Posted Date: 2015-04-10

Last Posted Date: 2025-05-18

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 113

Registration Number: NCT02414269

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge (Consent and Follow-Up), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Consent and Follow-Up), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen (Consent and Follow-Up), Montvale, New Jersey, United States

and more 3 locations

89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Glioblastoma Multiforme

Not Applicable

Completed

Conditions: Glioblastoma

Interventions: Drug: 89Zr-J591
Device: PET/CT Scan
Device: MRI
Other: Blood draw

First Posted Date: 2015-04-07

Last Posted Date: 2019-03-19

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 2

Registration Number: NCT02410577

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Use of Contrast Enhanced Spectral Mammography (CESM) for Women With Palpable Breast Abnormalities

Not Applicable

Completed

Conditions: Breast Abnormalities

Interventions: Other: Contrast Enhanced Spectral Mammography (CESM)

First Posted Date: 2015-04-02

Last Posted Date: 2024-06-28

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 249

Registration Number: NCT02406274

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Determinants of Bladder Cancer Recurrence Study (The DETER Study)

Active, not recruiting

Conditions: Bladder Cancer

Interventions: Behavioral: questionnaires
Other: Saliva and/or urine sample

First Posted Date: 2015-03-27

Last Posted Date: 2025-04-02

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 600

Registration Number: NCT02400944

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States

Health Related Quality of Life Following Hepatectomy for Colorectal Liver Metastasis: Global and Disease Specific Changes Over Time

Active, not recruiting

Conditions: Colorectal Liver Metastasis

Interventions: Behavioral: HRQoL questionnaires.

First Posted Date: 2015-03-26

Last Posted Date: 2025-04-09

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 219

Registration Number: NCT02399995

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge (Consent and Follow up), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen (Consent and Follow up), Montvale, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Commack (Consent and Follow up), Commack, New York, United States

and more 4 locations

Interrogation of Exosome-mediated Intercellular Signaling in Patients With Pancreatic Cancer

Recruiting

Conditions: Pancreatic Cancer
Benign Pancreatic Disease

First Posted Date: 2015-03-19

Last Posted Date: 2025-02-10

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 181

Registration Number: NCT02393703

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

DRIIVE (Data and Research on Interventions to Improve the Vehicular Environment)

Not Applicable

Completed

Conditions: Vehicular Environment

Interventions: Device: HEPA air purifier
Behavioral: questionnaires
Other: Log-book
Other: Urine sample

First Posted Date: 2015-03-06

Last Posted Date: 2021-10-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 39

Registration Number: NCT02381626

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Metastatic Spinal Bone Marrow Response to Radiation Therapy Using T1 Weighted Dynamic Contrast-Enhanced Perfusion

Active, not recruiting

Conditions: Solid Cancer
Metastatic Spinal Lesions

Interventions: Procedure: Dynamic contrast enhancement MRI

First Posted Date: 2015-03-03

Last Posted Date: 2024-10-29

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 25

Registration Number: NCT02376127

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy